An Exploratory Clinical Study of CDK4/6i Dalpiciclib Combined With AI Neoadjuvant Therapy for Stage II-III HR+/HER2- Breast Cancer
- First Posted Date
- 2024-09-25
- Last Posted Date
- 2024-09-25
- Lead Sponsor
- Jiangsu Famous Medical Technology Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT06613373
Pyrotinib Combined With Trastuzumab Subcutaneously Compared Intravenous Administration in the Treatment of HER2-positive Early Breast Cancer
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-08-05
- Last Posted Date
- 2024-08-05
- Lead Sponsor
- Jiangsu Famous Medical Technology Co., Ltd.
- Target Recruit Count
- 100
- Registration Number
- NCT06537674
Integrated Chinese and Western Medicine Specialized Disease Cohort for Colorectal Cancer
Not yet recruiting
- Conditions
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Jiangsu Famous Medical Technology Co., Ltd.
- Target Recruit Count
- 50000
- Registration Number
- NCT06136026
Xian-Lian-Jie-Du Optimization Decoction As an Adjuvant Treatment for Prevention of Recurrence of Colon Cancer
Phase 3
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-02-02
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Jiangsu Famous Medical Technology Co., Ltd.
- Target Recruit Count
- 730
- Registration Number
- NCT05709249
- Locations
- 🇨🇳
Jiangsu Province Hospital of Traditional Chinese Medicine, Nanjing, China
Treatment of Angina Pectoris After Coronary Revascularization With Integrated Traditional Chinese and Western Medicine
Completed
- Conditions
- Interventions
- First Posted Date
- 2022-08-01
- Last Posted Date
- 2022-08-01
- Lead Sponsor
- Jiangsu Famous Medical Technology Co., Ltd.
- Target Recruit Count
- 2000
- Registration Number
- NCT05482009
- Locations
- 🇨🇳
Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, Shenyang, Liaoning, China
Clinical Trial Scheme of Tanreqing Capsules in the Treatment of COVID-19
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2022-03-31
- Last Posted Date
- 2022-12-06
- Lead Sponsor
- Jiangsu Famous Medical Technology Co., Ltd.
- Target Recruit Count
- 480
- Registration Number
- NCT05305456
- Locations
- 🇨🇳
Huashan Hospital Affiliated to Fudan University, Shanghai, Shanghai, China
🇨🇳Shanghai Public Health Clinical Center, Shanghai, Shanghai, China
Clinical Study on Wuling Powder in Treating Metabolic Syndrome of Spleen Deficiency and Dampness
- First Posted Date
- 2021-03-23
- Last Posted Date
- 2021-03-23
- Lead Sponsor
- Jiangsu Famous Medical Technology Co., Ltd.
- Target Recruit Count
- 320
- Registration Number
- NCT04812236
Clinical Study of Huperzine A in the Treatment of Patients With Hypertensive Cerebral Hemorrhage
- First Posted Date
- 2020-08-12
- Last Posted Date
- 2020-08-12
- Lead Sponsor
- Jiangsu Famous Medical Technology Co., Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT04509323
- Locations
- 🇨🇳
The Fifth Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
TCM Differentiation and Treatment Protocol of COVID-19
- First Posted Date
- 2020-03-13
- Last Posted Date
- 2020-06-04
- Lead Sponsor
- Jiangsu Famous Medical Technology Co., Ltd.
- Target Recruit Count
- 340
- Registration Number
- NCT04306497
- Locations
- 🇨🇳
Huai'an fourth people's Hospital, Huaian, Jiangsu, China
Clinical Trial Scheme of Huangqi Guizhi Wuwu Decoction
- First Posted Date
- 2020-02-10
- Last Posted Date
- 2020-03-09
- Lead Sponsor
- Jiangsu Famous Medical Technology Co., Ltd.
- Target Recruit Count
- 360
- Registration Number
- NCT04261920
- Locations
- 🇨🇳
Affiliated Hospital of Nanjing University of TCM, Nanjing, Jiangsu, China
🇨🇳Jiangsu Province Hospital, Nanjing, Jiangsu, China
© Copyright 2024. All Rights Reserved by MedPath